Initiation of Month-to-month Minodronate Remedy at an Early Stage After Hip Fracture.
J Clin Densitom. 2016 Jul-Sep;19(three):352-Eight
Authors: Ohishi T, Fujita T, Suzuki D, Nishida T, Okabayashi R, Yamamoto Okay, Ushirozako H, Banno T, Matsuyama Y
The incidence of second hip fractures occurring inside a yr of preliminary fractures is 20%-45%. The excessive incidence of second hip fractures on this interval could be attributed to the fast bone loss that happens throughout this time. Restoring bone mass at an early stage after hip fractures is vital for stopping subsequent fractures. The purpose of this research was to research the efficacy of month-to-month minodronate remedy (50?mg/four?wk) for stopping bone loss over a 9-mo interval following hip fractures. Minodronate was administered month-to-month to 51 sufferers (44 females), starting inside three?mo after hip fracture surgical procedure. The imply (±normal deviation) age of the sufferers was 82.zero?±?zero.9?yr. Demographics, mobility standing, bone turnover makers, and bone mineral density (BMD) within the lumbar backbone and proximal femur (together with femoral neck and complete hip BMD) have been examined previous to and after 9?mo of therapy. Lumbar BMD was elevated by 2.7%?±?four.four% (p?<?zero.001) in comparison with the baseline values. Nonetheless, femoral neck and complete hip BMD didn’t considerably change. Bone formation and resorption markers each decreased by roughly 70% throughout therapy. Month-to-month therapy with minodronate didn’t adversely have an effect on the therapeutic course of on the fracture web site or the sufferers’ laboratory outcomes. The sufferers who have been independently cellular previous to damage exhibited higher restoration of BMD within the femoral neck through the 9-mo therapy interval. Month-to-month minodronate remedy through the early levels after hip fractures has favorable results on restoring general lumbar BMD and contralateral femoral neck BMD in sufferers with impartial mobility previous to fractures.
PMID: 27067298 [PubMed – indexed for MEDLINE]